Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP ; volume:18 ; number:1 ; day:12 ; month:9 ; year:2023 ; pages:1-14 ; date:12.2023
Molecular neurodegeneration ; 18, Heft 1 (12.9.2023), 1-14, 12.2023
- Urheber
-
Chiotis, Konstantinos
Johansson, Charlotte
Rodriguez-Vieitez, Elena
Ashton, Nicholas J.
Blennow, Kaj
Zetterberg, Henrik
Graff, Caroline
Nordberg, Agneta
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13024-023-00647-y
- URN
-
urn:nbn:de:101:1-2024020112465589151547
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chiotis, Konstantinos
- Johansson, Charlotte
- Rodriguez-Vieitez, Elena
- Ashton, Nicholas J.
- Blennow, Kaj
- Zetterberg, Henrik
- Graff, Caroline
- Nordberg, Agneta
- SpringerLink (Online service)
Ähnliche Objekte (12)
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Gene-variant specific effects of plasma amyloid-β levels in Swedish autosomal dominant Alzheimer disease
Performance on a pattern separation task by Alzheimer’s patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Gene-variant specific effects of plasma amyloid-β levels in Swedish autosomal dominant Alzheimer disease
Performance on a pattern separation task by Alzheimer’s patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Gene-variant specific effects of plasma amyloid-β levels in Swedish autosomal dominant Alzheimer disease